Related Experiment Video
Updated: May 20, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Efficacy of pembrolizumab monotherapy for advanced gingival malignant melanoma: A case report
Jie Li1, Chong-Tao Xu2, Wei Wu2
1Department of Stomatology, General Hospital, Tianjin Medical University, No. 154, Anshan Road, Heping District, Tianjin 300052, China; School of Dentistry, Stomatological Hospital, Tianjin Medical University, No. 12, Qixiangtai Road, Heping District, Tianjin 300070, China.
Abstract:
Oral malignant melanoma specifically denotes a rare subtype of melanoma originating in oral mucosa, characterized by a generally poor prognosis. Inhibitors targeting programmed cell death protein-1 or its ligand-1 (PD-1/PD-L1) have become widely accepted as primary treatments for malignant melanoma. The current report describes a unique case of advanced gingival malignant melanoma treated with pembrolizumab monotherapy in a 67-year-old Asian female. The report comprehensively evaluates the therapeutic potential of pembrolizumab, as well as its immune-related adverse events (irAEs).
Insights
This case study highlights pembrolizumab monotherapy for advanced oral malignant melanoma, a rare cancer. The treatment showed therapeutic potential while also detailing immune-related adverse events.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Oral malignant melanoma is a rare cancer with a poor prognosis.
- Programmed cell death protein-1 (PD-1)/PD-L1 inhibitors are established treatments for melanoma.
Observation:
- A case of advanced gingival malignant melanoma in a 67-year-old Asian female is presented.
- The patient was treated with pembrolizumab monotherapy.
Findings:
- Pembrolizumab demonstrated therapeutic potential in this advanced oral melanoma case.
- Immune-related adverse events (irAEs) associated with pembrolizumab were evaluated.
Implications:
- This case contributes to understanding pembrolizumab efficacy in rare oral melanomas.
- Further research into immunotherapy for oral cancers is warranted.
